Targeted therapy for non-small cell lung cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23721055.
- Also identified by DOI 10.1164/rccm.201301-0189PP.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The treatment of advanced non-small cell lung cancer has been with systemic chemotherapy and usually consists of a platinum doublet chemotherapy. The identification of somatic driver mutations has resulted in new drugs that target these mutations. This report discusses the two most important new targeted therapy drugs for the treatment of advanced non-small cell lung cancer that have these driver mutations.
Medical subject headings
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Pyrazoles
- Pyridines
- Quinazolines